Vitality Watch

Dossier clinicaltrials trial early 01-jul-2026
Small or early-phase human trial or pilot study

Halt Aging in Survivors of Blood Cancers

Key claim: A Phase 2 randomized controlled trial has been designed to test whether behavioral and exercise interventions can slow accelerated biological aging in older survivors of blood cancers.

Abstract

Older survivors of blood cancer are at a high risk of accelerated biological aging, which increases their risk of developing multiple aging-related conditions. Whereas physical exercise can improve overall health, older cancer survivors do not meet the recommended physical activity, highlighting the need to develop behavioral interventions to increase adherence. Several other knowledge gaps exist to implement exercise interventions in older survivors of blood cancer; the dose and duration of exercise necessary to slow biological aging in older blood cancer survivors remain unknown. To bridge these gaps in knowledge, we have designed a Phase 2 randomized control trial to test the effects of behavioral and exercise interventions on various outcomes.

Why this matters

Survivors of blood cancers show accelerated biological aging after treatment, making them a high-yield test population for exercise-as-geroprotector claims that in general populations are dominated by observational fitness–mortality associations. A Phase 2 RCT dedicated to this group could produce interventional evidence in a setting where the reverse-causation objection is weaker, but at this stage only the design is public — no outcome data on whether the intervention shifts biological-aging markers.

Source

Link

Briefing card

Halt Aging in Survivors of Blood Cancers
Stage: trial early · clinicaltrials · 01-jul-2026

If you are an older survivor of a blood cancer, this is a trial design announcement only — no results yet on whether the exercise-and-behavior program slows biological aging.

A Phase 2 randomized controlled trial has been designed to test whether behavioral and exercise interventions can slow accelerated biological aging in older survivors of blood cancers.

Cross-references (0)

None recorded — doctrine links and citations appear here as scans and citation sweeps find them.

External: nct:NCT07292272

build build 880 · 2bcef25 · 2026-11-18